REPROCELL
Graeme Macluskie is an experienced professional in the field of precision medicine and drug discovery. Currently serving as the Director of Precision Medicine at REPROCELL since May 2011, Graeme has focused on establishing a new business unit aimed at developing and enhancing precision medicine collaborations. Previously, Graeme held the position of Head of Research and Development at REPROCELL Europe, overseeing the advancement of various predictive drug discovery assays utilizing diverse techniques. Prior experience includes a role as Senior Supervisor/Study Director at Aptuit, where Graeme managed a range of in-vivo and in-vitro DMPK studies. Graeme holds a BSc (Hons) in Biochemistry and Pharmacology from the University of Strathclyde, completed in 2001.
This person is not in any teams
This person is not in any offices
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.